Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 20/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20929283 | 0.89 | CHRM1 (0.69) | CHRM1 | |
| SCHEMBL20917737 | 0.86 | CHRM1 (0.53) | CHRM1 | |
| SCHEMBL23972161 | 0.83 | CHRM1 (0.80) | CHRM1 | |
| SCHEMBL21859080 | 0.83 | CHRM1 (0.80) | CHRM1 | |
| SCHEMBL20917691 | 0.81 | CHRM1 (0.50) | CHRM1 | |
| SCHEMBL20929661 | 0.81 | CHRM1 (0.58) | CHRM1 | |
| SCHEMBL17440100 | 0.80 | CHRM1 (0.72) | CHRM1 | |
| SCHEMBL20929721 | 0.79 | CHRM1 (0.65) | CHRM1 | |
| SCHEMBL2226588 | 0.79 | CHRM1 (0.74) | CHRM1 | |
| SCHEMBL16937207 | 0.79 | CHRM1 (1.00) | CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3697790-B1 | HETEROARYL COMPOUNDS AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LTD (IN) | 2023-01-18 | — | — | EP | claimed |
| CN-111212840-B | Heteroaryl compounds as positive allosteric modulators of the muscarinic M1 receptor | 苏文生命科学有限公司 | 2022-07-22 | — | — | CN | claimed |
| US-11234979-B2 | Heteroaryl compounds as muscarinic M1 receptor positive allosteric modulators | SUVEN LIFE SCIENCES LIMITED (IN) | 2022-02-01 | — | — | US | claimed |
| EP-3697790-A1 | HETEROARYL COMPOUNDS AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Suven Life Sciences Limited (IN) | 2020-08-26 | — | — | EP | claimed |
| US-20200237761-A1 | HETEROARYL COMPOUNDS AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2020-07-30 | — | — | US | claimed |
| CN-111212840-A | Heteroaryl compounds as positive allosteric modulators of the muscarinic M1 receptor | 苏文生命科学有限公司 | 2020-05-29 | — | — | CN | claimed |
| WO-2019077517-A1 | HETEROARYL COMPOUNDS AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2019-04-25 | — | — | WO | claimed |
| EP-3697790-B1 | HETEROARYL COMPOUNDS AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LTD (IN) | 2023-01-18 | — | — | EP | disclosed |
| EP-3697790-B1 | HETEROARYL COMPOUNDS AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LTD (IN) | 2023-01-18 | — | — | EP | disclosed |
| CN-111212840-B | Heteroaryl compounds as positive allosteric modulators of the muscarinic M1 receptor | 苏文生命科学有限公司 | 2022-07-22 | — | — | CN | disclosed |
| US-11234979-B2 | Heteroaryl compounds as muscarinic M1 receptor positive allosteric modulators | SUVEN LIFE SCIENCES LIMITED (IN) | 2022-02-01 | — | — | US | disclosed |
| US-11234979-B2 | Heteroaryl compounds as muscarinic M1 receptor positive allosteric modulators | SUVEN LIFE SCIENCES LIMITED (IN) | 2022-02-01 | — | — | US | disclosed |
| US-20200237761-A1 | HETEROARYL COMPOUNDS AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2020-07-30 | — | — | US | disclosed |
| US-20200237761-A1 | HETEROARYL COMPOUNDS AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2020-07-30 | — | — | US | disclosed |
| CN-111212840-A | Heteroaryl compounds as positive allosteric modulators of the muscarinic M1 receptor | 苏文生命科学有限公司 | 2020-05-29 | — | — | CN | disclosed |
| WO-2019077517-A1 | HETEROARYL COMPOUNDS AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200237761-A1 | HETEROARYL COMPOUNDS AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885 |
| US-11234979-B2 | Heteroaryl compounds as muscarinic M1 receptor positive allosteric modulators | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.